Vesselon, Inc.Betting on Bubble Technology: From Alzheimer’s Treatment to Enhanced Cancer Drug DeliveryUltrasound-based therapies hold immense potential for improving patient care and advancing precision medicine — but it‘s the bubble, not…Feb 29Feb 29
Vesselon, Inc.Unlocking the Power of Precision: Antibody-Drug Conjugates in OncologyBy Clayton Larsen — President & CEO, Vesselon Inc.Feb 6Feb 6
Vesselon, Inc.Overview: Vesselon’s Transformative Coformulation MethodBy Clayton Larsen — President & CEO, Vesselon Inc.Jan 15Jan 15
Vesselon, Inc.Emerging Dynamics in the Biopharmaceutical Industry: An Analysis of Mergers and Acquisitions TrendsBy Vesselon, Inc.Dec 31, 2023Dec 31, 2023
Vesselon, Inc.How Vesselon Can Improve the Entire Class of RadiopharmaceuticalsBy Clayton Larsen — President & CEO, Vesselon, Inc.Nov 1, 2023Nov 1, 2023
Vesselon, Inc.How Vesselon Can Improve the Entire Class of Antibody-Drug ConjugatesBy Clayton Larsen — President & CEO, Vesselon, Inc.Oct 5, 2023Oct 5, 2023
Vesselon, Inc.Webinar: How Biophysics Can Change the Receive Characteristics of Characteristics of TumorsIt is believed that interstitial fluid pressure and solid stress are major obstacles preventing efficient delivery of macromolecules into…Aug 24, 2023Aug 24, 2023
Vesselon, Inc.Harnessing Sonoporation and Lipid Encapsulation: Vesselon’s Breakthrough in Drug DeliveryBy Clayton Larsen — President & CEO, Vesselon, Inc.Jul 5, 2023Jul 5, 2023
Vesselon, Inc.Limits of Keytruda?By Clayton Larsen — President & CEO, Vesselon, Inc.Jun 30, 2023Jun 30, 2023
